|
| related topics |
| {product, candidate, development} |
| {product, market, service} |
| {regulation, change, law} |
| {system, service, information} |
| {personnel, key, retain} |
| {acquisition, growth, future} |
| {provision, law, control} |
| {loan, real, estate} |
| {operation, natural, condition} |
| {stock, price, operating} |
|
|
The Company s success depends in part upon its ability to grow and develop its business.
The Company must adapt to rapid technological change.
The Company may be required to make certain future expenditures under contractual agreements with third parties.
The Company is subject to a complex and uncertain regulatory environment.
The Company s success depends upon its ability to attract and retain key personnel.
The Company s acquisitions, joint ventures and strategic alliances may not be successful.
The Company is dependent on interconnection agreements, permits and rights-of-way.
The Company s CLEC and Greenfield businesses must secure network elements from third parties.
The Company is dependent on its operating support systems.
The Company s long distance services are affected by its ability to establish effective termination agreements.
The market price of the Company s Common Stock has been and may be volatile.
The Company s investments in marketable securities and unconsolidated companies may not be successful.
Anti-takeover provisions may limit the ability of shareholders to effect a change in control of the Company.
Evolving corporate governance and public disclosure regulations may result in additional expenses and uncertainty.
Equipment failure and disasters may adversely affect the Company s operations.
The Company expects a continued decline in the voice long distance industry.
Full 10-K form ▸
|
|
| related documents |
| 1208208--2/24/2010--DIGITALGLOBE_INC |
| 351012--8/11/2006--INTERMAGNETICS_GENERAL_CORP |
| 943736--3/31/2006--MED-DESIGN_CORP |
| 64978--2/27/2009--MERCK_&_CO_INC |
| 64978--2/28/2008--MERCK_&_CO_INC |
| 914475--2/7/2006--NEUROCRINE_BIOSCIENCES_INC |
| 1041859--4/12/2006--CHILDRENS_PLACE_RETAIL_STORES_INC |
| 14272--2/22/2008--BRISTOL_MYERS_SQUIBB_CO |
| 858803--12/18/2006--AVANIR_PHARMACEUTICALS |
| 881890--6/14/2010--ABAXIS_INC |
| 886530--3/17/2008--DATATRAK_INTERNATIONAL_INC |
| 897075--3/17/2008--REPROS_THERAPEUTICS_INC. |
| 849636--3/16/2006--CORTEX_PHARMACEUTICALS_INC/DE/ |
| 886530--3/16/2009--DATATRAK_INTERNATIONAL_INC |
| 1062822--3/12/2007--LEXICON_GENETICS_INC/TX |
| 926763--3/16/2007--ASV_INC_/MN/ |
| 64978--2/28/2007--MERCK_&_CO_INC |
| 858803--12/21/2007--AVANIR_PHARMACEUTICALS |
| 858803--12/17/2008--AVANIR_PHARMACEUTICALS |
| 926763--3/16/2006--ASV_INC_/MN/ |
| 897075--3/16/2009--REPROS_THERAPEUTICS_INC. |
| 78003--2/29/2008--PFIZER_INC |
| 71478--3/15/2006--LIPID_SCIENCES_INC/ |
| 816284--2/17/2009--CELGENE_CORP_/DE/ |
| 1038133--2/22/2010--HESKA_CORP |
| 1038133--3/3/2008--HESKA_CORP |
| 1038133--3/16/2009--HESKA_CORP |
| 38074--6/14/2006--FOREST_LABORATORIES_INC |
| 310158--2/28/2007--SCHERING_PLOUGH_CORP |
| 28626--9/13/2007--LIFECORE_BIOMEDICAL_INC |
|